Which cancers are associated with FGFR alterations and how do you find out?

Alterations to fibroblast growth factor receptor (FGFR) genes are a prevalent potential driver of disease in oncology, with continuous activation of the FGFR pathway driving multiple tumourigenic processes across tumour types.[1][2][3][4] As altered FGFR signalling is common in a wide variety of cancers, FGFR alterations represent an important potential target.[3] The most commonly affected are urothelial carcinomas (UC) with FGFR alterations identified across all grades and stages of bladder cancer.[3][5]

The improved understanding of the role FGFR alterations have in oncology could mean you will be able to see your patients’ potential tumour drivers more clearly.[1][2][3][4]

Discuss with your pathologist the genetic tests that could provide detail on your patients’ potential tumour drivers[1][2][6][7]

Explore more

Learn more about FGFR alterations in oncology and their importance in UC:

What tumour types have FGFR alterations been detected in and how might they drive disease?
What could the identification of molecular subtypes and distinct genetic disease drivers mean for the management of advanced UC?
How could optimised genetic testing protocols help you identify what could be driving tumour growth in your patients?


Presta M et al. Pharmacol Ther 2017; 179: 171–187.
Ahmad I et al. Biochim Biophys Acta 2012; 1823(4): 850–860.
Helsten T et al. Clin Cancer Res 2016; 22(1): 259–267.
Corn PG et al. Clin Cancer Res 2013; 19(21): 5856–5866.
Di Martino E et al. Future Oncol 2016; 12(19): 2243–2263.
Mosele F et al. Ann Oncol 2020; S0923-7534(20): 39971–39973.
Malone ER et al. Genome Med 2020; 12: 8.
CP-212361 - February 2022